ArticleThe Journal of antimicrobial chemotherapy2021
Treating COVID-19: are we missing out the window of opportunity?
Article in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis.European journal of medical research · 2024Article
- Review
- Early alveolar epithelial cell necrosis is a potential driver of COVID-19-induced acute respiratory distress syndrome.iScience · 2023Article
- Comparison of clinical characteristics among patients infected with alpha vs. delta SARS-CoV-2 variants.Wiener klinische Wochenschrift · 2022Observational
- Utility of NO and HNitric oxide : biology and chemistry · 2022Review
- COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview.International journal of environmental research and public health · 2022Review
- Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2.Frontiers in pharmacology · 2022Article
- Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.Drug design, development and therapy · 2022Review
- Development of highly sensitive and rapid antigen detection assay for diagnosis of COVID-19 utilizing optical waveguide immunosensor.Journal of molecular cell biology · 2021Article
- The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies.Journal of clinical medicine · 2021Review
- Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.Pulmonary pharmacology & therapeutics · 2021Article
- Progress and pitfalls of a year of drug repurposing screens against COVID-19.Current opinion in virology · 2021Review
- Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes.Journal of infection and public health · 2021Article
- Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.Virology journal · 2021Review
- Efficacy of Telemedicine and Telemonitoring in At-Home Monitoring of Patients with COVID-19.Journal of clinical medicine · 2021Article
- Lessons learned: new insights on the role of cytokines in COVID-19.Nature immunology · 2021Article
- [Basic aspects of COVID-19 for management from primary care].Atencion primariaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.